HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC chairman

This article was originally published in The Rose Sheet

Executive Summary

President Bush nominates Jones Day partner Deborah Majoras as Federal Trade Commission chair May 11 to complete term of Timothy Muris, who plans to leave FTC this summer due to personal reasons. Announcement of his departure comes three years into his seven-year term; he will remain in his post until the confirmation process for his successor is complete. While at Jones Day, Majoras worked on Aventis' vitamins price-fixing case and Sandoz' (Novartis) brand name prescription drugs antitrust litigation. She previously served in the Department of Justice Antitrust Division from April 2001 until December 2003, attaining the position of principal deputy assistant attorney general...

President Bush nominates Jones Day partner Deborah Majoras as Federal Trade Commission chair May 11 to complete term of Timothy Muris, who plans to leave FTC this summer due to personal reasons. Announcement of his departure comes three years into his seven-year term; he will remain in his post until the confirmation process for his successor is complete. While at Jones Day, Majoras worked on Aventis' vitamins price-fixing case and Sandoz' (Novartis) brand name prescription drugs antitrust litigation. She previously served in the Department of Justice Antitrust Division from April 2001 until December 2003, attaining the position of principal deputy assistant attorney general....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel